The Latest Breaking News from AbbVie

AbbVie stock jumped Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, Humira.

December Nasdaq 100 E-Mini futures (NQZ24) are trending up +0.28% this morning as strong quarterly results from Alphabet boosted sentiment, while investors also awaited a fresh batch of U.S. economic data and earnings reports from “Magnificent Seven” companies Microsoft and Meta.

With AbbVie gearing up to release its third-quarter earnings later this month, analysts expect a marginal decline in earnings.

Looking for reliable yield? These three companies offer ever-increasing dividends and a lifetime of stability.

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

By investing in these dividend powerhouses, investors can achieve reliable income, mitigate risk through diversification, and potentially enjoy capital gains.

Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.

AbbVie has recently outperformed the Nasdaq, and Wall Street analysts are moderately optimistic about the stock’s prospects.